Loading...

LPH

LP

ALPHA COMPUTE CORP

(ALP)

2025 6-K

Major Acquisition Completed

27 May '26

GPU Infrastructure Update

21 May '26

Compute Agreement

13 May '26

GPU Acquisition

29 Apr '26

Name Change Filing

20 Apr '26

Acquisition Announcement

20 Mar '26

Nasdaq Compliance Notice

2 Mar '26

ATM Offering Agreement

17 Feb '26

Share Exchange Unwound

10 Feb '26

Board Changes

6 Feb '26

Strategic Roadmap Update

28 Jan '26

Filing Amendment

21 Jan '26

Share Offering Announcement

15 Jan '26

Filing Summary

12 Jan '26

ATM Agreement Termination

9 Jan '26

Investor Repurchase Action

31 Dec '25

Settlement Agreement

31 Dec '25

Director Resignation

23 Dec '25

ATM Agreement Filing

25 Nov '25

Clarification Issued

21 Nov '25

Management Change

23 Oct '25

Filing Details

22 Oct '25

ATM Agreement Update

9 Oct '25

Private Placement Closed

25 Sep '25

Financing Update

23 Sep '25

ATM Offering Agreement

4 Sep '25

Company Name Change

3 Sep '25

Filing Summary

25 Jul '25

ATM Offering Agreement

27 Jun '25

Regained Compliance

25 Jun '25

Share Issuance

9 Jun '25

Auditor Change

29 May '25

Preclinical Results

28 Apr '25

Promising Results

27 Mar '25

Director Compensation Plan

13 Mar '25

Patient Enrollment Resumed

12 Mar '25

Nasdaq Compliance Update

12 Feb '25

Share Sale Announcement

30 Jan '25

Company Update

6 Jan '25

Acquisition Intent

17 Dec '24

Management Change

13 Dec '24

Nasdaq Compliance Notice

12 Dec '24

Management Changes

5 Dec '24

Filing Report

26 Nov '24

6-K Filing Summary

26 Nov '24

Management Changes

4 Oct '24

Compliance Regained

3 Sep '24

Filing Update

27 Aug '24

Financial Report

27 Aug '24

Filing Overview

15 Aug '24

Filing Update

13 Aug '24

Board Changes

30 Apr '24

Portage Filing Update

12 Apr '24

Nasdaq Compliance Notice

8 Mar '24

Filing Summary

6 Mar '24

Filing Report

28 Feb '24

Filing Summary

28 Feb '24

Filing Report

18 Jan '24

Filing Notification

4 Jan '24

External Links:

SEC

On January 6, 2025, Portage Biotech Inc. announced the re-launch of its subsidiary, Cyncado Therapeutics Inc., which will focus on adenosine receptor antagonists, with Peter Molloy appointed as CEO.

AI Assistant

ALPHA COMPUTE CORP

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.